Current Options for Third-Line Treatment of Metastatic Colorectal Cancer

Area of Science:

• Oncology
• Pharmacology
• Gastroenterology

Background:

• Metastatic colorectal cancer (CRC) treatment options were historically limited.
• Limited efficacy of traditional therapies necessitates novel therapeutic strategies for refractory disease.

Purpose of the Study:

• To review the efficacy and safety of regorafenib and trifluridine/tipiracil (TAS-102) in refractory metastatic CRC.
• To discuss the sequencing of these agents based on patient characteristics and tolerability.

Main Methods:

• Review of clinical trial data and published literature on regorafenib and trifluridine/tipiracil.
• Analysis of safety profiles, including common adverse events and management strategies.
• Discussion of factors influencing treatment decisions and sequencing.

Main Results:

• Both regorafenib and trifluridine/tipiracil significantly improve overall survival in patients with refractory metastatic CRC.
• Regorafenib is associated with hand-foot skin reaction and fatigue; alternative dosing may improve tolerability.
• Trifluridine/tipiracil is primarily associated with myelosuppression.

Conclusions:

• Regorafenib and trifluridine/tipiracil represent important advances in the treatment of refractory metastatic CRC.
• Optimal sequencing of these agents should consider individual patient profiles, comorbidities, and prior treatment responses.
• Ongoing research aims to further define the role and optimal utilization of these agents in CRC management.